On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older. The medication is an injectable branded Ebglyss and will be available in ...

--New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin long-term ...

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD). Both products now will be available to a significantly larger patient ...

Please provide your email address to receive an email when new articles are posted on . Ebglyss is a targeted interleukin-13 inhibitor approved for the treatment of moderate-to-severe atopic ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm Hawaii 2026 (Jan. 25-29), showcasing a comprehensive body of evidence across ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Injections included six for APG777, 11 for ...

While eczema is a common skin condition, it can manifest in many different ways. And with so much possible variation, it's ...

EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling with high binding affinity. 2,3,4 The cytokine IL-13 is a primary cytokine in atopic dermatitis, driving the type ...